Intraoperative radiotherapy in elderly patients with breast cancer: long-term follow-up results of the prospective phase II trial TARGIT-E.

Date publication

décembre 2025

Journal

BMC cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MARTIN Etienne

Tous les auteurs :
Sperk E, Lemanski C, Neumaier C, Lauer J, Siefert V, Völker R, Lindner C, Niehoff P, Tallet AR, Racadot S, Petit A, Pazos M, Le-Blanc Onfroy M, Martin E, Reuter C, Hermann RM, Pohl F, Friedrichs K, Würschmidt F, Pigorsch S, Kolberg HC, Graf H, Brunner TB, Malter W, Park-Simon TW, Brucker C, Fleckenstein J, Petersen C, Tuschy B, Wilken EE, Büttner S, Sütterlin M, Flyger H, Wenz F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41345599

Résumé

Whole-breast radiotherapy (WBRT) after breast-conserving surgery (BCS) in older patients can be challenging due to the increased presence of comorbidities, comedication, the presence of a pacemaker or difficulties in traveling to treatment every day. Challenging times, such as the pandemic, can also lead to RT not being performed despite the indication. Very short treatment regimens are therefor of special interest in this population reducing overall treatment time and radiation exposure. TARGIT-E is a phase II trial investigating intraoperative radiotherapy (IORT) during BCS in elderly patients. We report long-term follow-up results of TARGIT-E.

Mots clés

Accelerated partial breast irradiation (APBI), Breast cancer, Breast-conserving surgery, Cosmetic outcome, Elderly patients, Intraoperative radiotherapy (IORT), TARGIT, Toxicity

Référence

BMC Cancer. 2025 12 4;: